Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 3/20 | 0.55 |
| ▸ | CTSL | P07711 | 1/20 | 0.53 |
| ▸ | MLYCD | O95822 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.50 |
| ▸ | CTSD | P07339 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.50 |
| ▸ | ANPEP | P15144 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15843890 | 0.87 | SCN9A (0.57) | CACNA1BMLYCDSCN9A | |
| SCHEMBL15844420 | 0.87 | SCN9A (0.57) | CACNA1BMLYCDSCN9A | |
| SCHEMBL15843891 | 0.87 | SCN9A (0.57) | CACNA1BMLYCDSCN9A | |
| SCHEMBL28747286 | 0.84 | TP53 (0.52) | CTSLMLYCDMEN1KMT2ACTSD | |
| SCHEMBL20088471 | 0.84 | SCN9A (0.54) | CACNA1BCTSLSCN9AANPEP | |
| SCHEMBL20088353 | 0.84 | SCN9A (0.54) | CACNA1BCTSLSCN9AANPEP | |
| SCHEMBL13103578 | 0.83 | MLYCD (0.59) | MLYCDMEN1KMT2AEPHX1PLA2G1B | |
| SCHEMBL28747285 | 0.82 | CTSL (0.48) | CTSLMLYCDMEN1KMT2ACTSD | |
| SCHEMBL27684529 | 0.81 | CCR2 (0.56) | CTSLMLYCDMEN1KMT2ACTSD | |
| SCHEMBL6173159 | 0.81 | HTR2A (0.57) | MLYCDMEN1KMT2AEPHX1PLA2G1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9688615-B2 | Benzimidazole inhibitors of the sodium channel | DEGIACOMO, INTERIM TRUSTEE, MARK G. (US) | 2017-06-27 | — | — | US | disclosed |
| US-20150361032-A1 | BENZIMIDAZOLE INHIBITORS OF THE SODIUM CHANNEL | NATIONAL CENTER FOR ADDICTION STUDIES AND TREATMENT FOUNDATION | 2015-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150361032-A1 | BENZIMIDAZOLE INHIBITORS OF THE SODIUM CHANNEL | SCN1A, KCNJ11, KCNJ1 | CACNA1B 17/4885CTSL 4238/4885MLYCD 1956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.